替雷利珠单抗联合化疗药物治疗晚期非小细胞肺癌的疗效及对血清肿瘤标志物的影响探讨  

Efficacy of tislelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer and its influence on serum tumor markers

作　　者：李星辉 朱平香 LI Xing-hui;ZHU Ping-xiang(Department of Oncology,Ruijin People's Hospital,Ruijin 342500,China)

机构地区：[1]瑞金市人民医院肿瘤内科,342500 [2]瑞金市妇幼保健院药剂科,342500

出　　处：《中国现代药物应用》2024年第7期91-94,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨替雷利珠单抗联合化疗药物治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效及对血清肿瘤标志物水平的影响。方法回顾性分析106例晚期非小细胞肺癌患者的临床资料,根据治疗方法不同分为对照组(吉西他滨单药治疗)和观察组(吉西他滨联合替雷利珠单抗治疗),每组53例。观察并比较两组患者临床疗效、药物不良反应发生情况以及治疗前后健康状况调查简表(SF-36)评分和糖类抗原125(CA125)、癌胚抗原(CEA)、神经特异性烯化酶(NSE)水平。结果观察组疾病缓解率(92.5%)明显高于对照组(77.4%)(P<0.05)。观察组患者治疗前的SF-36评分为(48.57±3.56)分,治疗后SF-36评分为(86.34±5.32)分;对照组患者治疗前的SF-36评分为(48.61±3.58)分,治疗后SF-36评分为(63.28±4.63)分。与治疗前比较,两组患者治疗后的SF-36评分均有明显改善,且与对照组治疗后比较,观察组患者治疗后的SF-36评分明显更高(P<0.05)。观察组患者治疗前CA125为(105.86±5.29)U/ml,CEA为(65.76±0.23)μg/L,NSE为(38.56±2.30)ng/ml,治疗后CA125为(32.92±2.38)U/ml,CEA为(16.85±2.23)μg/L,NSE为(6.54±1.67)ng/ml;对照组患者治疗前CA125为(105.88±5.30)U/ml,CEA为(65.79±0.25)μg/L,NSE为(38.62±2.31)ng/ml,治疗后CA125为(63.32±2.31)U/ml,CEA为(29.27±2.29)μg/L,NSE为(22.15±1.88)ng/ml。治疗前,两组患者血清CA125、CEA、NSE水平比较,差异无统计学意义(P>0.05);与治疗前比较,两组患者治疗后血清CA125、CEA、NSE水平均有所降低,且与对照组治疗后比较,观察组患者治疗后血清CA125、CEA、NSE水平明显更低(P<0.05)。治疗过程中,与对照组(20.8%)比较,观察组患者药物不良反应发生率(3.8%)显著降低(P<0.05)。结论晚期肺癌患者经替雷利珠单抗与化药联合治疗后临床症状明显得到改善,临床总有效率显著升高,血清中肿瘤标志物水平降低,患者的生活质量水平得到提高,且治疗过程中发生的药物不良反应明显降低�Objective To explore the clinical efficacy of tislelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on serum tumor markers.Methods The clinical data of 106 patients with advanced non-small cell lung cancer were retrospectively analyzed,and they were divided into a control group(gemcitabine monotherapy)and an observation group(gemcitabine combined with tislelizumab)according to different treatment methods,with 53 cases in each group.Observation and comparison were made on clinical efficacy,occurrence of adverse drug reactions,36-item short-form health survey(SF-36)score,carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and neuron-specific enolase(NSE)levels before and after treatment.Results The remission rate of disease in the observation group(92.5%)was significantly higher than that in the control group(77.4%)(P<0.05).In the observation group,the SF-36 score was(48.57±3.56)points before treatment and(86.34±5.32)points after treatment.In the control group,the SF-36 score was(48.61±3.58)points before treatment and(63.28±4.63)points after treatment.Compared with before treatment,the SF-36 scores in both groups improved significantly after treatment,and the SF-36 score in the observation group was significantly higher than that in the control group after treatment(P<0.05).In the observation group,CA125 was(105.86±5.29)U/ml,CEA was(65.76±0.23)μg/L,and NSE was(38.56±2.30)ng/ml before treatment,and after treatment,CA125 was(32.92±2.38)U/ml,CEA was(16.85±2.23)μg/L,and NSE was(6.54±1.67)ng/ml.In the control group,CA125 was(105.88±5.30)U/ml,CEA was(65.79±0.25)μg/L,and NSE was(38.62±2.31)ng/ml before treatment,and after treatment,CA125 was(63.32±2.31)U/ml,CEA was(29.27±2.29)μg/L,and NSE was(22.15±1.88)ng/ml.Before treatment,there was no significant difference in serum CA125,CEA and NSE levels between the two groups(P>0.05).Compared with before treatment,the serum CA125,CEA and NSE levels in both groups decreased after treatme

关 键 词：替雷利珠单抗 吉西他滨 晚期肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]